

drug name	side effect	side effect	side effect	side effect	side effect	interacts with
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		

interacts with	interacts with	disease name	disease category
		Adenocarcinoma	Cancer
		Complementary component deficiency	Immunological
		IgG receptor I, phagocytic, familial deficiency of	Immunological
		Lupus erythematosus	Connective tissue disorder
		Lymphoma	Cancer
		Neutropenia	Hematological
		Nonsmall cell lung cancer	Cancer
		Viral infection	Immunological
		Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980	Cancer
		C1q deficiency, type A	Immunological
		C1q deficiency, type B	Immunological
		C1s deficiency, isolated	Immunological
		Lupus nephritis, susceptibility to	Connective tissue disorder
		Lymphoma, progression of	Cancer
		Neutropenia, alloimmune neonatal	Hematological
		Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980	Cancer
		Viral infections, recurrent	Immunological
		Interleukin-2 receptor, alpha chain, deficiency of	Immunological
		Severe combined immunodeficiency	Immunological
		Combined immunodeficiency	Immunological
		Combined immunodeficiency, X-linked, moderate, 312863	Immunological
		Severe combined immunodeficiency, X-linked, 300400	Immunological
		Asthma	Respiratory
		Asthma	Respiratory
		Complementary component deficiency	Immunological
		Complementary component deficiency	Immunological
		Dementia	Neurological

drug category	product name	company name
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation

clinical trial title
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

clinical trial start date	clinical trial completion date	clinical trial participants	clinical trial status	clinical trial condition
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease

clinical trial condition	clinical trial address	clinical trial institution	clinical trial address	clinical trial main researcher
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD

clinical trial condition
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Mouth Neoplasms
Melanoma
Melanoma
Melanoma
Melanoma
Melanoma

[illegible]



	Dementia	Neurological
	IgG receptor I, phagocytic, familial deficiency of	Immunological
	IgG receptor I, phagocytic, familial deficiency of	Immunological
	Lupus erythematosus	Connective tissue disorder
	Lupus erythematosus	Connective tissue disorder
	Lymphoma	Cancer
	Lymphoma	Cancer
	Malaria	Immunological
	Malaria	Immunological
	Migraine	Neurological
	Migraine	Neurological
	Myocardial infarction	Cardiovascular
	Myocardial infarction	Cardiovascular
	Neutropenia	Hematological
	Neutropenia	Hematological
	Sepsis	Immunological

[illegible]









[illegible]

	Sepsis	Immunological
	Viral infection	Immunological
	Viral infection	Immunological
	Asthma, susceptibility to, 600807	Respiratory
	Asthma, susceptibility to, 600807	Respiratory
	C1q deficiency, type A	Immunological
	C1q deficiency, type A	Immunological
	C1q deficiency, type B	Immunological
	C1q deficiency, type B	Immunological
	C1s deficiency, isolated	Immunological
	C1s deficiency, isolated	Immunological
	Dementia, vascular, susceptibility to	Neurological
	Dementia, vascular, susceptibility to	Neurological
	Lupus nephritis, susceptibility to	Connective tissue disorder
	Lupus nephritis, susceptibility to	Connective tissue disorder
	Lymphoma, progression of	Cancer



[illegible]



[illegible]





[illegible]

	Lymphoma, progression of	Cancer
	Malaria, cerebral, susceptibility to	Immunological
	Malaria, cerebral, susceptibility to	Immunological
	Migraine without aura, susceptibility to, 157300	Neurological
	Migraine without aura, susceptibility to, 157300	Neurological
	Myocardial infarction, susceptibility to	Cardiovascular
	Myocardial infarction, susceptibility to	Cardiovascular
	Neutropenia, alloimmune neonatal	Hematological
	Neutropenia, alloimmune neonatal	Hematological
	Septic shock, susceptibility to	Immunological
	Septic shock, susceptibility to	Immunological
	Viral infections, recurrent	Immunological
	Viral infections, recurrent	Immunological
	Alzheimer disease	Neurological
	Conjunctivitis, ligneous	Ophthalmological
	Plasminogen deficiency	Hematological
	Alzheimer disease, late-onset, susceptibility to, 104300	Neurological
	Conjunctivitis, ligneous, 217090	Ophthalmological
	Plasminogen Tochigi disease	Hematological

[illegible]



## Can We Miss Pigmented Lesions in Psoriasis Patients?

# Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra	
---	--

## Can We Miss Pigmented Lesions in Psoriasis Patients?

# Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Additional of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

## Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Can We Miss Pigmented Lesions in Psoriasis Patients?

### Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft Versus Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Can We Miss Diamond-Blackfan Anemia in Pediatric Patients?

Can we Miss Pigmented Lesions in Hematopoietic Patients?

### Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft versus Host Disease (GVHD) Prophylaxis in Stem Cell Transplantation

---

---

---

---

---

\_\_\_\_\_

2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease

Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center	University of Michigan Cancer Center	John Levine, MD

## Melanoma

Melanoma

Melanoma

## Melanoma

Melanoma

Melanoma

Melanoma

Melanoma

Melanoma

## Melanoma

Melanoma

Melanoma

## Melanoma

[illegible]

		Complementary component deficiency	Immunological
		Complementary component deficiency	Immunological
		Glanzmann thrombasthenia	Hematological
		Glanzmann thrombasthenia	Hematological
		IgG receptor I, phagocytic, familial deficiency of	Immunological
		IgG receptor I, phagocytic, familial deficiency of	Immunological
		Lupus erythematosus	Connective tissue disorder
		Lupus erythematosus	Connective tissue disorder
		Lymphoma	Cancer
		Lymphoma	Cancer
		Neutropenia	Hematological
		Neutropenia	Hematological
		Viral infection	Immunological
		Viral infection	Immunological
		C1q deficiency, type A	Immunological
		C1q deficiency, type A	Immunological
		C1q deficiency, type B	Immunological
		C1q deficiency, type B	Immunological
		C1s deficiency, isolated	Immunological
		C1s deficiency, isolated	Immunological
		Glanzmann thrombasthenia, type B	Hematological
		Glanzmann thrombasthenia, type B	Hematological
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	<a href="#">Endocrine</a>
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory

Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc





[illegible]

[illegible]

[illegible]

[illegible]

salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory

[illegible]

[illegible]

[illegible]



[illegible]

[illegible]

[illegible]

salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular

Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium

[illegible]

[illegible]

[illegible]



[illegible]

[illegible]

salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, diminished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory

Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Pramosone E	Ferndale Laboratories, Inc.

[illegible]

[illegible]

[illegible]